Ketoconazole Topical

Contraindicated

Ketoconazole Topical Alfuzosin UroXatral Increased alfuzosin exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Alprazolam Xanax Increased ALPRAZolam exposure and an increased risk of ALPRAZolam-related adverse reactions Details Ketoconazole Topical Amiodarone Nexterone Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Aripiprazole Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Aripiprazole Lauroxil Aristada Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Artemether Increased artemether/lumefantrine exposure, an increased risk of QT interval prolongation, reduced ketoconazole exposure and reduc... Details Ketoconazole Topical Astemizole Increased astemizole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Atazanavir Reyataz Increased atazanavir exposure, increased ketoconazole exposure and an increased risk for QT interval prolongation Details Ketoconazole Topical Bedaquiline Sirturo Increased bedaquiline exposure and an increased risk for QT interval prolongation Details Ketoconazole Topical Bepridil An increased risk of QT interval prolongation Details Ketoconazole Topical Bromocriptine Cycloset Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ketoconazole Topical Buprenorphine Belbuca Increased buprenorphine exposure, an increased risk of buprenorphine-related adverse events and an increased risk of QT interval p... Details Ketoconazole Topical Ceritinib Zykadia Increased ceritinib exposure, increased ketoconazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Cisapride Propulsid® Increased risk of QT interval prolongation Details Ketoconazole Topical Clarithromycin Biaxin Increased clarithromycin exposure, an increased ketoconazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Clozapine Clozaril Increased cloZAPine exposure and an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Ketoconazole Topical Colchicine Colcrys Increased colchicine exposure and an increased risk of colchicine toxicity Details Ketoconazole Topical Conivaptan Vaprisol Increased conivaptan exposure and an increased CYP3A substrate exposure Details Ketoconazole Topical Crizotinib Xalkori Increased crizotinib exposure, increased ketoconazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Dabrafenib Tafinlar Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Dihydroergotamine Brekiya Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ketoconazole Topical Dofetilide Tikosyn Increased dofetilide exposure, an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) and an i... Details Ketoconazole Topical Domperidone Increased domperidone exposure and increased risk of QT interval prolongation Details Ketoconazole Topical Dordaviprone An increased risk of QT interval prolongation, increased dordaviprone exposure and an increased risk of dordaviprone-related adver... Details Ketoconazole Topical Dronedarone Multaq Increased dronedarone exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Eletriptan Relpax Increased eletriptan exposure Details Ketoconazole Topical Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse events and an increased risk of QT interval prolo... Details Ketoconazole Topical Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Ketoconazole Topical Entrectinib Rozlytrek Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Eplerenone Inspra Increased eplerenone exposure Details Ketoconazole Topical Ergoloid Mesylates Alkergot® Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ketoconazole Topical Ergonovine Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ketoconazole Topical Ergotamine Ergomar Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Ketoconazole Topical Erythromycin Erythrocin Stearate Increased erythromycin exposure, an increased ketoconazole exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Felodipine Plendil® Increased felodipine exposure and additive negative inotropic effect Details Ketoconazole Topical Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Ketoconazole Topical Flibanserin Addyi Increased flibanserin exposure and an increased flibanserin-related adverse effects Details Ketoconazole Topical Fluconazole Diflucan Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Ketoconazole Topical Gepirone Exxua Increased gepirone exposure, an increased risk of gepirone-related adverse effects, an increased risk of QT interval prolongation... Details Ketoconazole Topical Gepotidacin Blujepa Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details